Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Repligen Corp (RGEN)

Repligen Corp (RGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
1 High-Flying Stock with Exciting Potential and 2 to Keep Off Your Radar

1 High-Flying Stock with Exciting Potential and 2 to Keep Off Your Radar

LUCK : 9.12 (-0.65%)
NOW : 1,025.75 (-1.39%)
RGEN : 126.19 (-0.25%)
Repligen Corporation to Present at Upcoming May Investor Conferences

RGEN : 126.19 (-0.25%)
RGEN Q1 Earnings Call: Repligen Delivers Above-Consensus Revenue, Raises Sales Outlook Amid Tariff Uncertainty

RGEN Q1 Earnings Call: Repligen Delivers Above-Consensus Revenue, Raises Sales Outlook Amid Tariff Uncertainty

RGEN : 126.19 (-0.25%)
Repligen's Q1 Earnings Beat Estimates, Revenues Surge Y/Y

Repligen Corporation RGEN reported first-quarter 2025 adjusted earnings per share of 39 cents, which beat the Zacks Consensus Estimate of 35 cents. The company had recorded adjusted earnings of 30 cents...

BEAM : 17.66 (-1.31%)
IMCR : 31.00 (+2.07%)
RGEN : 126.19 (-0.25%)
ADMA : 20.19 (+2.54%)
Repligen (NASDAQ:RGEN) Posts Better-Than-Expected Sales In Q1, Full-Year Outlook Slightly Exceeds Expectations

Repligen (NASDAQ:RGEN) Posts Better-Than-Expected Sales In Q1, Full-Year Outlook Slightly Exceeds Expectations

RGEN : 126.19 (-0.25%)
Repligen (NASDAQ:RGEN) Posts Better-Than-Expected Sales In Q1, Full-Year Outlook Slightly Exceeds Expectations

Repligen (NASDAQ:RGEN) Posts Better-Than-Expected Sales In Q1, Full-Year Outlook Slightly Exceeds Expectations

RGEN : 126.19 (-0.25%)
Repligen: Q1 Earnings Snapshot

Repligen: Q1 Earnings Snapshot

RGEN : 126.19 (-0.25%)
Repligen Reports First Quarter 2025 Financial Results

RGEN : 126.19 (-0.25%)
Repligen (RGEN) Q1 Earnings: What To Expect

Repligen (RGEN) Q1 Earnings: What To Expect

MEDP : 305.98 (+0.10%)
RGEN : 126.19 (-0.25%)
WST : 217.22 (+0.27%)
3 Healthcare Stocks That Concern Us

3 Healthcare Stocks That Concern Us

MYGN : 4.43 (+7.26%)
RGEN : 126.19 (-0.25%)
IQV : 143.54 (+0.50%)

Barchart Exclusives

Should You Buy This Dividend-Paying Gold Stock in 2025?
With gold prices soaring above $3,200 an ounce, Kinross Gold is poised for further growth. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar